Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NeuroPace (NPCE) Cash & Equivalents (2020 - 2026)

NeuroPace has reported Cash & Equivalents over the past 7 years, most recently at $14.8 million for Q1 2026.

  • For Q1 2026, Cash & Equivalents fell 45.3% year-over-year to $14.8 million; the TTM value through Mar 2026 reached $14.8 million, down 45.3%, while the annual FY2025 figure was $21.7 million, 61.52% up from the prior year.
  • Cash & Equivalents for Q1 2026 was $14.8 million at NeuroPace, down from $21.7 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $27.0 million in Q1 2025 and troughed at $5.7 million in Q3 2022.
  • A 5-year average of $13.5 million and a median of $13.0 million in 2024 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: tumbled 81.75% in 2022 and later surged 173.4% in 2023.
  • Year by year, Cash & Equivalents stood at $6.6 million in 2022, then surged by 173.4% to $18.1 million in 2023, then fell by 25.63% to $13.4 million in 2024, then surged by 61.52% to $21.7 million in 2025, then plummeted by 31.87% to $14.8 million in 2026.
  • Business Quant data shows Cash & Equivalents for NPCE at $14.8 million in Q1 2026, $21.7 million in Q4 2025, and $20.6 million in Q3 2025.